JOIN THE FIRST EVER CONFERENCE CONNECTING HUMAN BIOTECHS WITH THE ANIMAL HEALTH INDUSTRY.

Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health – this summit aims to connect the two industries.

De-Risk and validate human products, by testing in outbred animal patients with naturally-occurring diseases. **HUMAN PRODUCT SUPPORT**

Supply unmet and underserved medical needs in veterinary health, and work at the forefront of innovation in the animal health industry. **ANIMAL HEALTH INNOVATION**

Generate non-dilutive income through licensing and royalty revenue at low operational cost, to support human projects and the wider business. **ECONOMIC OPPORTUNITIES**

Maximize IP assets by leveraging products in both human and animal health, and secure both with patent term extension strategies. **IP & PATENT STRATEGY**

When I first thought about animal health it seemed so far away from what we are doing, then I realized the overlap and how it was a natural fit.”

Sean Ekins, CEO COLLABORATIONS PHARMA
**EXPLORE OPPORTUNITIES** for generating non-dilutive income, validating and de-risking human research, and maximizing IP assets in our myth-busting case studies of human biotech and animal health partnerships.

**FORGE RELATIONSHIPS** with animal health executives in pre-scheduled 1-on-1 meetings, and discuss research collaborations, deal-licensing and other business development opportunities.

**DISCUSS UNMET MEDICAL NEEDS** in veterinary health, and learn how the regulatory road works, how the industry operates and which technologies are of interest to animal pharmaceutical and nutrition companies.

**IDENTIFY COMMERCIAL POTENTIAL** in your translational technologies with investors and advisory firms specializing in the veterinary health industry.

---

**ATTENDING**

**EXPLORE OPPORTUNITIES**

*Attendees: 100+
Meetings per person: 20+
One-to-one meetings confirmed at Animal Health Investment London 2017*

---

**IDENTIFY COMMERCIAL POTENTIAL**

- 40% Human Biotechnology Companies
- 40% Animal Health Companies
- 20% Investment & Service Providers

---

The Onsite EXPERIENCE

**European Microbiome Congress**

**Animal Health Investment Europe**

www.humanbiotechanimalhealth.com • + 44 (0) 203 696 2920
Who should attend?

HUMAN BIOTECHNOLOGY
- Chief Executive Officers, Chief Scientific Officers, Chief Business Officers and corporate leadership from human biotechs working on technologies in fields including but not limited to:
  - Oncology
  - Immunology
  - Infectious Disease
  - Antibiotic Alternatives
  - Pain & Inflammation
  - Allergic Diseases and Allergy
  - Metabolic Disease
  - Diagnostics
  - Nutritional Health
  - And More!

ANIMAL HEALTH
- Directors of External Innovation & Business Development from leading Animal Health Pharmaceutical and Nutrition Companies.
- Market Intelligence and Consultancy Providers

INVESTMENT & SERVICE PROVIDERS
- Private Equity & Venture Capital Investors
- Investment Bankers & M&A advisors
- Legal Advisory

Industry success stories

Successful licensing deals between human biotechnology and animal health companies:

- Gilead Sciences licensed Tanovea-CA1 to VetDC.
- RaQualia Pharmaceuticals licensed ENTYCE and Galliprant to Aratana Therapeutics.
- Pacira Pharmaceuticals licensed NOCITA to Aratana Therapeutics.
- Karyopharm licensed Verdinexor to Anivive Lifesciences.
2018
SPEAKERS

Kristin Bloink
Senior Director, Research & External Innovation
Elanco
26+ years experience in pharmaceutical companies such as Novartis and Elanco (Eli Lilly).

Scott Brown
VP, Head of External Innovation
z忒is
20+ years experience in pharmaceutical companies such as Pharmacia, Pfizer and Zoetis.

James Wilson
Professor, Gene Therapy Program
Penn
30+ years as a geneticist. Founded Scout Bio, resulting in the first, and only, commercially approved gene therapy in the western hemisphere.

Atsushi Nagahisa
Founder & Innovation Advisor
RaQualia
33+ years industry experience. Raised $111 million to launch RaQualia, the first, organic spin-out in Pfizer's history; then raised $83 million in an IPO.

Steven St. Peter
CEO
ARATANA
30+ years experience in Investment & Investment Banking and Pharmaceutical industries.

Peter Hanson
Chief Veterinary Officer and EVP Clinical Operations & CMC
CENTREXION
21+ years industry experience in companies such as Merck and Merial.

Christine Adriani
Director, Translation In Vivo Models Global Research Platform
SANOFI GENZYME
10+ years industry experience in companies such as Merck and Sanofi.

Linda Rhodes
VMD, PhD
26+ years industry experience in companies such as Merck and Merial. Ex-CEO of Aratana Therapeutics.

Brian Kopp
Partner
Stonehaven Consulting
20+ years industry experience. Ex-CFO of Elanco.

Stephen Martin
Head of Global Pharmaceutical R&D
Boehringer Ingelheim
27+ years experience in pharmaceutical companies such as Pharmacia, Pfizer, Novartis, Merial and Boehringer Ingelheim.

Sean Ekins
CEO
21+ years industry experience in pharmaceutical companies such as Eli Lilly and Pfizer.
AGENDA
MARCH 12, 2018

You’re Invited!
Exclusive Networking Evening
6 x 15 min meetings
Kisaco Research is pleased to invite you to an exclusive evening of business partnering and networking for those who want to make the most of their time in Boston. This is a perfect opportunity for biotechs and animal health companies to meet and connect before the Summit officially begins on Tuesday.

MARCH 13, 2018

OPENING KEYNOTE: A New Era: Market Opportunity in the Modern Animal Health Industry
Hosted by Elanco

Private Pre-Scheduled Meetings
4 x 15 min meetings

The Value Proposition for Human Biotechs
James Wilson, Professor, Gene Therapy Program, University of Pennsylvania

Case Study: RaQualia Pharma Inc. and Aratana Therapeutics
Atsushi Nagahisa, Founder & Innovation Advisor, RaQualia Pharma Inc.
Steven St. Peter, CEO, Aratana Therapeutics

Immunomodulation: Common Pathways in Human and Animal Health
Christine Adreani, Director, Translational In Vivo Models Global Research Platform, Sanofi Genzyme

Private Pre-Scheduled Meetings
2 x 15 min meetings

In Conversation with: Human Biotech & Animal Pharmaceutical
Scott Brown, VP, Head of External Innovation, Zoetis
Peter Hanson, Exec VP Clinical Operations & CMC, Chief Veterinary Officer, Centrexion
Sean Ekins, CEO, Collaborations Pharmaceuticals, Inc.
Moderated by: Brian Kopp, Partner, Stonehaven Consulting

De-risking Drug Development with Translational Comparative Medical Research
Kristin Bloink, Senior Director, Research & External Innovation, Elanco
We believe insights gained from human medicine can help better inform our animal-health innovation efforts. Likewise, we know that our R&D efforts in veterinary medicine can help inform and perhaps even accelerate innovation in human medicine.”

– Scott Brown, VP External Innovation, ZOETIS
BOSTON, USA

Kisaco Research is pleased to offer attendees of the Human Biotech & Animal Health Business Partnering Summit a discounted rate at various nearby hotels for the duration of the Congress. Please check back in the coming weeks for updates.

PRICING INFORMATION

<table>
<thead>
<tr>
<th>PRICING INFORMATION</th>
<th>DELEGATE PASS</th>
<th>INVESTOR PASS</th>
<th>START-UP PASS (COMPANIES PRE-SERIES B FUNDING)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Bird 1</td>
<td>Early Bird 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Book before December 20)</td>
<td>(Book before January 26)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$1,599</td>
<td>$1,899</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard Rate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Book after January 26)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$2,199</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INVESTOR PASS</td>
<td></td>
<td>$599</td>
<td></td>
</tr>
<tr>
<td>START-UP PASS</td>
<td>$699*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(COMPANIES PRE-SERIES B FUNDING)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Email Jessica if you'd like to bring your investors at the VIP rate of $199: jp@kisacoresearch.com

BOOK A TEAM TO SAVE MORE!
Industry Rates Only: Team discounts cannot be combined with any other discount or offer

<table>
<thead>
<tr>
<th>BOOK A TEAM TO SAVE MORE!</th>
<th>Book a Team of 3+</th>
<th>Save an Additional 10% Off</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Book a Team of 5+</td>
<td>Save an Additional 15% Off</td>
</tr>
</tbody>
</table>

Payment Terms:
- Please note that a $70 processing fee will apply to any invoices requested.
- All Prices are in USD
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- Kisaco Research reserves the right to ensure that the correct pricing categories are applied to all registrants
- All discount offers cannot be combined with any other offer.
- Please view our Cancellation Policy.